Latest Governance News

Challenger Gold has secured the final Environmental Impact Assessment amendment for its Hualilán Gold Project, enabling ore haulage and toll milling at the Casposo plant. This milestone unlocks a low-capital pathway to early cash flow while advancing the project’s development.

Metal Bank Limited has announced a non-renounceable entitlement offer to raise approximately $2.32 million, partially underwritten, to fund its Western Australia gold strategy and Queensland graphite exploration. The offer closes on 31 October 2025 and coincides with a strategic acquisition of gold assets from Hastings Technology Metals.

First Lithium Limited has secured an $800,000 loan facility and received encouraging signals from the Mali government on license renewals for its key lithium projects, setting the stage for resource estimation and further development.

Power Minerals confirms a high-grade carbonatite hard rock intrusion at its Santa Anna Rare Earth Elements Project in Brazil, with promising grades and ongoing drilling aimed at defining a maiden resource estimate.

Metals Australia Ltd reveals a 3.3-fold increase in its Lac Carheil graphite resource alongside promising assay results for precious and base metals, setting the stage for value-added by-product recovery.

Lunnon Metals has reported promising drilling results at its Plentiful gold prospect, extending the mineralised structure to over 450 metres and revealing consistent widths and modest gold grades. These findings enhance the scale of opportunities within its Kambalda Gold & Nickel Project.

TPC Consolidated and Wollar Solar Holding have agreed to extend key deadlines in their acquisition scheme as they await crucial FIRB approval, pushing the timeline into early 2026.

Variscan Mines has successfully completed the majority of the second tranche of its $2.5 million capital raise, issuing over 330 million shares and nearly 200 million options to support its zinc-lead project in Spain.

Australian Clinical Labs has reached a $6.2 million settlement with the Australian Information Commissioner to resolve a Federal Court case stemming from a 2022 cyberattack on its newly acquired Medlab Pathology business.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.

Imagion Biosystems has completed the second tranche of its $3.5 million placement, raising $2.85 million to advance its proprietary MagSense® imaging technology targeting breast, prostate, and ovarian cancers.

AssetOwl Limited has locked in a $281,654 convertible note funding from a related party, adding to its financing options as it navigates shareholder approval and potential share dilution.